Because IHC experiments detected variability in the expression level of NMT2 in breast adenocarcinoma tissues samples, and NMT2 protein loss correlated with better survival outcomes in breast cancer patients, we sought to determine if inhibiting NMT function in breast cancer lines would reduce cell viability in vitro. The gene discussed is NMT2; the disease is breast carcinoma.